ImmuPharma plc (LON:IMM – Get Free Report) traded down 11.7% during mid-day trading on Thursday . The company traded as low as GBX 3.75 ($0.05) and last traded at GBX 3.80 ($0.05). 14,936,349 shares were traded during trading, a decline of 25% from the average session volume of 19,799,125 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Price Performance
The company has a market capitalization of £16.15 million, a PE ratio of -6.57 and a beta of 1.53. The company’s fifty day moving average is GBX 2.67 and its 200-day moving average is GBX 2.01.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- What is the NASDAQ Stock Exchange?
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Industrial Products Stocks Investing
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Overbought Stocks Explained: Should You Trade Them?
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
